What are biosimilars? The Pharmacy Times® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
Retacrit gains FDA approval as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, chemotherapy, or in patients with HIV.
The Pharmacy Times® Biosimilars condition center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of biosimilars, and the newest data from all phases of clinical trials and studies.
Among its other resources are a wealth of videos including interviews with thought leaders and experts in biosimilars, and moderated panel discussions about the best practices and key methods for treating complex cases, utilizing the newest biologic medical products replicating medical products originally manufactured by popular companies.